Gilead prices COVID-19 drug candidate remdesivir at $2,340 per patient

Gilead has tied up with generic drugmakers based in India and Pakistan, including Cipla Ltd and Hetero Labs Ltd, to make and supply remdesivir in 127 developing countries. Cipla's version is priced at less than 5,000 Indian rupees ($66.24), while Hetero Lab's version is priced at 5,400 rupees.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3eEWqXf
via IFTTT